Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive (AURA2)
What is the purpose of this trial?
To assess the efficacy of AZD9291 by assessment of Objective Response Rate (ORR).
- 18 Years and older
- Astra Zeneca, L.P.
- Last Updated:
- Study HIC#: